BIO
Bio-Rad Laboratories A·NYSE
--
--(--)
--
--(--)
BIO fundamentals
Bio-Rad Laboratories A (BIO) released its earnings on Feb 12, 2026: revenue was 693.20M (YoY +3.85%), beat estimates; EPS was 2.51 (YoY -13.45%), missed estimates.
Revenue / YoY
693.20M
+3.85%
EPS / YoY
2.51
-13.45%
Report date
Feb 12, 2026
BIO Earnings Call Summary for Q4,2025
- Revenue Resilience: 2025 net sales $2.583B (0.7% YoY), with Q4 2025 non-GAAP EPS $2.51 vs. $2.90 in 2024.
- ddPCR Success: QX700 platform drove mid-single-digit growth, with Stilla acquisition accreting 6-12 months earlier than expected.
- Challenges Ahead: 2026 guidance for 0.5-1.5% revenue growth, with process chromatography expected to decline mid-teens due to regulatory changes.
- Cash Flow Strength: 2025 free cash flow $375M (138% of non-GAAP net income), with $285M available for buybacks in 2026.
- Strategic Focus: Operational efficiency, margin expansion, and selective M&A to drive long-term growth.
EPS
Actual | 1.91 | 1.61 | 3 | 4.01 | 5.21 | 3.54 | 3.71 | 3.21 | 4.94 | 3.38 | 2.6 | 3.31 | 3.34 | 3 | 2.33 | 3.1 | 2.29 | 3.11 | 2.01 | 2.9 | 2.54 | 2.61 | 2.26 | 2.51 | ||||||||||
Forecast | 1.5651 | 1.2233 | 1.8023 | 3.295 | 2.9946 | 2.6644 | 2.4373 | 2.8507 | 3.3689 | 2.7987 | 2.7821 | 3.4484 | 3.5422 | 2.679 | 2.7821 | 2.8181 | 2.1463 | 2.0145 | 1.1572 | 2.8684 | 1.8103 | 1.734 | 1.954 | 2.7079 | ||||||||||
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | +22.04% | +31.61% | +66.45% | +21.70% | +73.98% | +32.86% | +52.22% | +12.60% | +46.64% | +20.77% | -6.55% | -4.01% | -5.71% | +11.98% | -16.25% | +10.00% | +6.70% | +54.38% | +73.70% | +1.10% | +40.31% | +50.52% | +15.66% | -7.31% |
Revenue
Actual | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 571.64M | 536.88M | 647.26M | 789.84M | 726.80M | 715.90M | 747.05M | 732.77M | 700.10M | 691.10M | 680.80M | 730.29M | 676.84M | 681.11M | 632.12M | 681.18M | 610.80M | 638.48M | 649.73M | 667.50M | 585.40M | 651.60M | 653.00M | 693.20M |
Forecast | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 546.85M | 517.06M | 570.57M | 686.79M | 660.98M | 646.07M | 664.57M | 730.26M | 672.63M | 682.62M | 679.94M | 742.26M | 689.96M | 697.96M | 689.50M | 685.00M | 619.09M | 645.79M | 628.18M | 679.29M | 573.26M | 615.20M | 652.24M | 688.81M |
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | +4.53% | +3.83% | +13.44% | +15.00% | +9.96% | +10.81% | +12.41% | +0.34% | +4.08% | +1.24% | +0.13% | -1.61% | -1.90% | -2.41% | -8.32% | -0.56% | -1.34% | -1.13% | +3.43% | -1.74% | +2.12% | +5.92% | +0.12% | +0.64% |
Earnings Call
You can ask Aime
What is the revenue and EPS growth rate for Bio-Rad Laboratories A year over year?What does Bio-Rad Laboratories A do and what are its main business segments?What were the key takeaways from Bio-Rad Laboratories A's earnings call?What guidance did Bio-Rad Laboratories A's management provide for the next earnings period?What is Bio-Rad Laboratories A's gross profit margin?What is the market's earnings forecast for Bio-Rad Laboratories A next quarter?What is Bio-Rad Laboratories A's latest dividend and current dividend yield?What factors drove the changes in Bio-Rad Laboratories A's revenue and profit?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
